Abstract

PurposeThe purpose of this study is to compare optic disc dose (ODD) between 125I and 103Pd Collaborative Ocular Melanoma Study (COMS) plaques in ocular brachytherapy.MethodsA previously validated in-house brachytherapy dose calculation program was used for ODD calculations. ODD was calculated as a function of tumor margin-to-optic disc distance (DT) up to 5 mm for various tumor basal dimensions (BDs), for a prescription depth of 5 mm, and for standard and notched COMS plaques loaded with 125I (model: IAI-125A) and 103Pd (model: IAPd-103A) seeds. ODD calculations were repeated for prescription depths from 2 mm to 10 mm in 1 mm intervals. A prescribed dose of 85 Gy (irradiation time: 120 hours) was normalized to each prescription depth. Dose conversion factors (DCFs) for each prescription depth were calculated by taking a ratio of [total reference air kerma (TRAK) per seed]prescription depth to [TRAK per seed]5 mm. ODD reduction by notched COMS plaques was calculated for each prescription depth by subtracting ODD for notched COMS plaques from ODD for standard COMS plaques.ResultsTrends of ODD as a function of DT for various BDs are similar between the two seed types in both standard and notched COMS plaques. However, due to the energy difference, there exists a transition distance (dt) for each BD in each plaque at which ODD for 125I COMS plaques equals that for 103Pd COMS plaques. For small BDs, at DT <dt, ODD for 103Pd COMS plaques is higher than that for 125I COMS plaques while at DT >dt, the opposite is observed. For the largest 1-3 BD(s), contrarily, dt occurs within the tumor, and thus, ODD for 125I COMS plaquesis always higher. Trends of ODD reduction by notched COMS plaques as a function of DT for various BDs are the same for the two seed types except that maximum ODD reduction by 103Pd COMS notched plaques is larger. DCF increases with increasing prescription depth for both seed types.ConclusionsThere exist ODD differences between 125I and 103Pd COMS plaques and the differences depend on DT, BD, plaque size, and prescription depth.

Highlights

  • In the mid-1980s, the Collaborative Ocular Melanoma Study (COMS) established standardized methods of 125I plaque brachytherapy for medium-sized (apical height from 2.5 mm to 10.0 mm and maximal tumor basal dimension (BD) of ≤16 mm) choroidal melanomas and conducted a prospective randomized clinical trial comparing 125I plaque brachytherapy with enucleation [1,2,3]

  • Trends of optic disc dose (ODD) as a function of DT for various basal dimensions (BDs) are similar between the two seed types in both standard and notched COMS plaques

  • For the largest 1-3 BD(s), contrarily, dt occurs within the tumor, and ODD for 125I COMS plaques is always higher

Read more

Summary

Introduction

In the mid-1980s, the Collaborative Ocular Melanoma Study (COMS) established standardized methods of 125I plaque brachytherapy for medium-sized (apical height from 2.5 mm to 10.0 mm and maximal tumor basal dimension (BD) of ≤16 mm) choroidal melanomas and conducted a prospective randomized clinical trial comparing 125I plaque brachytherapy with enucleation [1,2,3]. Several dosimetry studies have supported these clinical outcomes: with 103Pd plaques, the dose is increased within the tumor but decreased in most normal ocular structures when the equivalent dose is prescribed to the tumor apex [8,9,10,11]. This is due to the lower photon energy of 103Pd seeds resulting in a more rapid dose fall-off with distance compared with 125I seeds [9]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call